StreetInsider.com News Articles

Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens Before ESC Congress

Tue, 25 Aug 2026 04:14:42 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $30.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst commented, " At the European Society of Cardiology (ESC) Congress 2026 later this week, AstraZeneca (AZN, NC) will present detailed results from the previously announced, failed Ph3 CARDIOTTRansform study evaluating the siRNA therapeutic Wainua (eplontersen) in ATTR-CM. In July, the company reported that eplontersen failed to meet the study's primary efficacy endpoint in a population where ~80% of patients were receiving background transthyretin stabilizer therapy. We expect the full data presentation to provide important insights into the challenges of demonstrating clinical

Form 4 Intellia Therapeutics, For: Aug 20 Filed by: LEONARD JOHN M

Mon, 24 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26968093.html

Form 4 Intellia Therapeutics, For: Aug 20 Filed by: LEONARD JOHN M

Mon, 24 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26968093.html

Form 144 Intellia Therapeutics, Filed by: LEONARD JOHN M

Thu, 20 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260820/26956109.html

Form 144 Intellia Therapeutics, Filed by: LEONARD JOHN M

Thu, 20 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260820/26956109.html

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 38,200 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

Form SCHEDULE 13G Intellia Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26888710.html

Form SCHEDULE 13G Intellia Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 09:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26888710.html

Evercore ISI Upgrades Intellia Therapeutics (NTLA) to Outperform

Thu, 06 Aug 2026 16:17:14 -0400

Evercore ISI analyst Jonathan Miller upgraded Intellia Therapeutics (NASDAQ: NTLA) from In Line to Outperform with a price target of $24.00 (from $16.00).

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $10.97 yesterday.

Evercore ISI Upgrades Intellia Therapeutics (NTLA) to Outperform

Thu, 06 Aug 2026 16:17:14 -0400

Evercore ISI analyst Jonathan Miller upgraded Intellia Therapeutics (NASDAQ: NTLA) from In Line to Outperform with a price target of $24.00 (from $16.00).

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $10.97 yesterday.

Form 10-Q Intellia Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883710.html

Form 10-Q Intellia Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883710.html

Intellia Therapeutics (NTLA) PT Lowered to $49 at Jefferies

Thu, 06 Aug 2026 12:55:57 -0400

Jefferies analyst Maury Raycroft lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $49.00 (from $50.00) while maintaining a Buy rating.

Form 8-K Intellia Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:45:00 -0400

si-local-file:///var/storage/secattach/20260806/26878966.html

Form 8-K Intellia Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:45:00 -0400

si-local-file:///var/storage/secattach/20260806/26878966.html

Intellia Therapeutics (NTLA) Reports In-Line Q2 EPS

Thu, 06 Aug 2026 07:24:55 -0400

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($0.80), in-line with the analyst estimate of ($0.80). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $13.18 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Thu, 06 Aug 2026 07:00:00 -0400

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Thu, 06 Aug 2026 07:00:00 -0400

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Thu, 06 Aug 2026 07:00:00 -0400

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Thu, 06 Aug 2026 07:00:00 -0400

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Thu, 06 Aug 2026 07:00:00 -0400

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Thu, 06 Aug 2026 07:00:00 -0400

Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least